Company Overview

Royalty Pharma plc is a leading buyer of biopharmaceutical royalties and a significant provider of capital to the life sciences industry. The company operates within the biopharmaceutical, healthcare finance, and life sciences investment sectors, focusing on acquiring royalty interests in approved and late-stage therapies. Its primary revenue is generated from cash flows linked to sales of drugs developed and commercialized by third-party pharmaceutical and biotechnology companies.

The company’s portfolio is diversified across therapeutic areas, including rare diseases, oncology, immunology, neurology, and infectious diseases, with exposure to blockbuster and high-growth medicines. Royalty Pharma’s strategic advantage lies in its scale, permanent capital base, and specialized expertise in valuing life sciences intellectual property. Founded in 1996, the firm pioneered the biopharmaceutical royalty investment model and has evolved from a niche investment vehicle into a publicly traded company listed on Nasdaq following its initial public offering in 2020.

Business Operations

Royalty Pharma operates as a single, integrated business focused on the acquisition and management of royalty interests, though its activities are often described across functional areas such as Royalty Acquisitions, Portfolio Management, and Capital Formation. The company generates revenue by purchasing existing royalties from originators such as universities, research hospitals, foundations, and pharmaceutical companies, as well as by funding drug development in exchange for future royalty streams.

The company does not manufacture or commercialize drugs and has no exposure to clinical or regulatory development risk for approved products. Its operations are global, with royalty interests tied to drug sales across multiple international markets. Royalty Pharma controls a portfolio of royalty and milestone interests related to therapies commercialized by major pharmaceutical partners, and it operates through subsidiaries including Royalty Pharma AG and other wholly owned entities used for investment and financing activities.

Strategic Position & Investments

Royalty Pharma’s strategy centers on deploying large-scale, long-duration capital into high-quality biopharmaceutical assets with strong clinical and commercial profiles. Growth initiatives include acquiring royalties on newly approved drugs, investing in late-stage clinical assets, and entering structured financings that provide capital to innovators while securing future economic participation. The company has also expanded into funding drug development directly through its development-stage royalty platform.

Major investments have included royalty interests tied to leading medicines such as treatments for cystic fibrosis, hematologic cancers, and autoimmune diseases. Royalty Pharma maintains a selective approach to acquisitions, emphasizing assets with durable intellectual property, established reimbursement, and diversified payer exposure. Its investment activity spans both approved products and select late-stage pipeline assets, reflecting a balance between current income and long-term growth.

Geographic Footprint

Royalty Pharma is headquartered in New York, United States, and maintains significant operations in Europe, with a principal office in London, United Kingdom. The company’s investment portfolio is globally diversified, with royalty cash flows derived from drug sales in North America, Europe, Asia-Pacific, and other international markets.

While the company’s physical footprint is relatively concentrated, its economic exposure is worldwide due to the global commercialization of the therapies underlying its royalty interests. Royalty Pharma’s international presence supports relationships with multinational pharmaceutical companies, academic institutions, and research organizations across multiple continents.

Leadership & Governance

Royalty Pharma was founded by Pablo Legorreta, who has played a central role in shaping the company’s long-term, disciplined investment philosophy. The leadership team emphasizes conservative financial management, portfolio diversification, and alignment with innovation-driven partners across the life sciences ecosystem. Governance practices are designed to support transparency, shareholder alignment, and long-term value creation.

Key executives include:

• Pablo Legorreta – Founder and Chief Executive Officer
• Terrance Coyne – Chief Financial Officer
• Rafael Hoffman – Chief Portfolio Officer
• Kristin C. Kelley – General Counsel and Secretary
• Sarah E. Alspach – Chief Communications Officer

The management team collectively brings experience across investment management, pharmaceuticals, finance, and legal governance, supporting Royalty Pharma’s position as a specialized and scalable platform in biopharmaceutical royalty investing.